Chemomab Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • CMMB

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.56
  • (As of Wednesday Closing)

Chemomab Therapeutics General Information

Description

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10 Habarzel Street, Building C, 10th Floor
  • Tel Aviv 6971010
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 10 Habarzel Street, Building C, 10th Floor
  • Tel Aviv 6971010
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chemomab Therapeutics Stock Performance

As of 18-Nov-2026, Chemomab Therapeutics’s stock price is $1.56. Its current market cap is $12.5M with 8.05M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.56 $1.64 $0.92 - $2.99 $12.5M 8.05M 103K -$1.04

Chemomab Therapeutics Financials Summary

As of 30-Jun-2026, Chemomab Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,622 100 15,094 (20,708)
Revenue 0 0 0 0
EBITDA (7,851) (9,497) (14,686) (25,392)
Net Income (7,553) (8,995) (13,945) (24,221)
Total Assets 10,238 13,812 16,964 22,151
Total Debt 0 0 324 392
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Chemomab Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Chemomab Therapeutics‘s full profile, request access.

Request a free trial

Chemomab Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Chemomab Therapeutics‘s full profile, request access.

Request a free trial

Chemomab Therapeutics Patents

Chemomab Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021259682-A1 Method of treatment using anti-ccl24 antibody Pending 22-Apr-2020
CA-3172627-A1 Method of treatment using anti-ccl24 antibody Pending 22-Apr-2020
EP-4139352-A1 Method of treatment using anti-ccl24 antibody Pending 22-Apr-2020
US-20230235037-A1 Method of treatment using anti-ccl24 antibody Pending 22-Apr-2020
WO-2021214759-A1 Method of treatment using anti-ccl24 antibody Inactive 22-Apr-2020 C07K16/24
To view Chemomab Therapeutics’s complete patent history, request access »

Chemomab Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chemomab Therapeutics Acquisitions (2)

Chemomab Therapeutics’s most recent deal was a Reverse Merger with Scipher Medicine for . The deal was made on 09-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Scipher Medicine 09-Jul-2026 Reverse Merger Discovery Tools (Healthcare)
Anchiano Therapeutics 16-Mar-2021 Merger/Acquisition Drug Discovery
To view Chemomab Therapeutics’s complete acquisitions history, request access »

Chemomab Therapeutics FAQs

  • When was Chemomab Therapeutics founded?

    Chemomab Therapeutics was founded in 2011.

  • Where is Chemomab Therapeutics headquartered?

    Chemomab Therapeutics is headquartered in Tel Aviv, Israel.

  • What is the size of Chemomab Therapeutics?

    Chemomab Therapeutics has 12 total employees.

  • What industry is Chemomab Therapeutics in?

    Chemomab Therapeutics’s primary industry is Drug Discovery.

  • Is Chemomab Therapeutics a private or public company?

    Chemomab Therapeutics is a Public company.

  • What is Chemomab Therapeutics’s stock symbol?

    The ticker symbol for Chemomab Therapeutics is CMMB.

  • What is the current stock price of Chemomab Therapeutics?

    As of 18-Nov-2026 the stock price of Chemomab Therapeutics is $1.56.

  • What is the current market cap of Chemomab Therapeutics?

    The current market capitalization of Chemomab Therapeutics is $12.5M.

  • What is Chemomab Therapeutics’s annual earnings per share (EPS)?

    Chemomab Therapeutics’s EPS for 12 months was -$1.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process